{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:44:43Z","timestamp":1777866283768,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.vaccine.2026.128387","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T10:29:51Z","timestamp":1772188191000},"page":"128387","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Prevalence of high-risk human papillomavirus among women with different HPV-vaccination status in Sichuan, China"],"prefix":"10.1016","volume":"77","author":[{"given":"He","family":"Lixia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Liangcheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhang","family":"Dongmei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin","family":"Changsha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He","family":"Junyong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128387_bb0005","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ijc.2910520513","article-title":"The causal link between human papillomavirus and invasive cervical cancer: a population-based case\u2013control study in Colombia and Spain","volume":"52","author":"Munoz","year":"1992","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2026.128387_bb0010","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/jnci\/85.12.958","article-title":"Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia","volume":"85","author":"Schiffman","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2026.128387_bb0015","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.biopha.2014.12.041","article-title":"Overview of high-risk HPV\u2019S 16 and 18 infected cervical cancer: pathogenesis to prevention","volume":"70","author":"Ramakrishnan","year":"2015","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.vaccine.2026.128387_bb0020","unstructured":"HPV Type-Specific Prevalence a Decade after the Implementation of the Vaccination Program: Results from a Pilot Study."},{"issue":"8","key":"10.1016\/j.vaccine.2026.128387_bb0025","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.2706","article-title":"Prevalence of Human papillomavirus infection among women born in the 1990s vs the 1980s and association with HPV vaccination in the US","volume":"3","author":"Shahmoradi","year":"2022","journal-title":"JAMA Health Forum"},{"issue":"365","key":"10.1016\/j.vaccine.2026.128387_bb0030","article-title":"Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study","author":"Palmer","year":"2019","journal-title":"BMJ"},{"issue":"10316","key":"10.1016\/j.vaccine.2026.128387_bb0035","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(21)02178-4","article-title":"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study","volume":"398","author":"Falcaro","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128387_bb0040","doi-asserted-by":"crossref","unstructured":"Chow EPF, Carter A, Vickers T, Fairley CK, McNulty A, Guy RJ, Regan DG, Grulich AE, Callander D, Khawar L, Machalek DA, Donovan B. Effect on genital warts in Australian female and heterosexual male individuals after introduction of the national human papillomavirus gender-neutral vaccination programme: an analysis of national sentinel surveillance data from 2004-18. Lancet Infect Dis 2021 21(12):1747\u20131756.","DOI":"10.1016\/S1473-3099(21)00071-2"},{"key":"10.1016\/j.vaccine.2026.128387_bb0045","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-077341","article-title":"Effect of the HPV vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia by socioeconomic deprivation in England: population based observational study","volume":"385","author":"Falcaro","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2026.128387_bb0050","doi-asserted-by":"crossref","unstructured":"Drolet M, B\u00e9nard \u00c9, P\u00e9rez N, Brisson M; HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet 2019; 10;394 (10197):497-509.","DOI":"10.1097\/OGX.0000000000000724"},{"key":"10.1016\/j.vaccine.2026.128387_bb0055","unstructured":"Vaccine and Immunization Branch, Chinese Preventive Medicine Association Expert consensus on immunoprophylaxis of human papillomavirus-related diseasesChinese journal of preventive medicine.2019, 53:1218\u20131235, Chin J Prev Med."},{"key":"10.1016\/j.vaccine.2026.128387_bb0060","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1001\/jama.287.16.2114","article-title":"Forum group members; Bethesda 2001 workshop. The 2001 Bethesda system. Terminology for reporting results of cervical cytology","volume":"287","author":"Solomon","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2026.128387_bb0065","unstructured":"IARC. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 2007;90:1\u2013636."},{"issue":"1","key":"10.1016\/j.vaccine.2026.128387_bb0070","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1186\/s12879-019-4038-8","article-title":"Distribution of high-risk HPV types among women in Sichuan province, China: a cross-sectional study","volume":"19","author":"He","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128387_bb0075","doi-asserted-by":"crossref","unstructured":"Osborne SL, Tabrizi SN, Brotherton JM, Cornall AM, Wark JD, Wrede CD, Jayasinghe Y, Gertig DM, Pitts MK, Garland SM; VACCINE Study group. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program. Vaccine 2015 33(1):201\u20138.","DOI":"10.1016\/j.vaccine.2014.10.045"},{"key":"10.1016\/j.vaccine.2026.128387_bb0080","doi-asserted-by":"crossref","unstructured":"Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED Jr, Ngan Y, Petersen LK, Lazcano-Ponce E, Pitisuttithum P, Restrepo JA, Stuart G, Woelber L, Yang YC, Cuzick J, Garland SM, Huh W, Kjaer SK, Bautista OM, Chan IS, Chen J, Gesser R, Moeller E, Ritter M, Vuocolo S, Luxembourg A; Broad Spectrum HPV Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015 372(8):711\u201323.","DOI":"10.1056\/NEJMoa1405044"},{"key":"10.1016\/j.vaccine.2026.128387_bb0085","doi-asserted-by":"crossref","unstructured":"Kahren van Eer, Marit Middeldorp, Tsira Dzebisasjvili, Najima Lamkaraf, Hester E de Melker, Renske D M Steenbergen, Audrey J King, Effects of 2 and 3 vaccinations with the bivalent human papillomavirus (HPV) vaccine on the prevalence and load of HPV in clearing and persistent infections in young women, Lancet Infect Dis, 2023,Vol.228(No.8):1012\u20131022.","DOI":"10.1093\/infdis\/jiad080"},{"key":"10.1016\/j.vaccine.2026.128387_bb0090","doi-asserted-by":"crossref","unstructured":"Lynge E, Thamsborg L, Larsen LG, Christensen J, Johansen T, Hariri J, Christiansen S, Rygaard C, Andersen B. Prevalence of high-risk human papillomavirus after HPV-vaccination in Denmark. Int J Cancer 2020 147(12):3446\u20133452.","DOI":"10.1002\/ijc.33157"},{"issue":"26","key":"10.1016\/j.vaccine.2026.128387_bb0095","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1016\/j.vaccine.2018.05.019","article-title":"Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs","volume":"36","author":"Dillner","year":"2018","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128387_bb0100","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1542\/peds.2011-3587","article-title":"Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction","volume":"130","author":"Kahn","year":"2012","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128387_bb0105","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1038\/s41467-024-47909-x","article-title":"Concomitant human papillomavirus (HPV) vaccination and screening for elimination of HPV and cervical cancer","volume":"15","author":"Arroyo M\u00fchr","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128387_bb0110","doi-asserted-by":"crossref","unstructured":"Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Liu B, Bateson D, McNamee K, Garefalakis M, Phillips S, Cummins E, Malloy M, Garland SM. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis 2014 14(10):958\u201366.","DOI":"10.1016\/S1473-3099(14)70841-2"},{"issue":"29","key":"10.1016\/j.vaccine.2026.128387_bb0115","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1016\/j.vaccine.2019.04.099","article-title":"Declines in HPV vaccine type prevalence in women screened for cervical cancer in the United States: evidence of direct and herd effects of vaccination","volume":"37","author":"Markowitz","year":"2019","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128387_bb0120","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3390\/v16081245","article-title":"Update on effects of the prophylactic HPV vaccines on HPV type prevalence and cervical pathology","volume":"16","author":"Hampson","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2026.128387_bb0125","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fimmu.2020.00188","article-title":"The use of both therapeutic and prophylactic vaccines in the therapy of papillomavirus disease","volume":"11","author":"Garbuglia","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128387_bb0130","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s12916-024-03538-1","article-title":"Influences of HPV disease perceptions, vaccine accessibility, and information exposure on social media on HPV vaccination uptake among 11,678 mothers with daughters aged 9-17 years in China: a cross-sectional study","volume":"22","author":"Lin","year":"2024","journal-title":"BMC Med"},{"issue":"14","key":"10.1016\/j.vaccine.2026.128387_bb0135","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV vaccination and the risk of invasive cervical Cancer","volume":"383","author":"Lei","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26001957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26001957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:22:29Z","timestamp":1777537349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26001957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":27,"alternative-id":["S0264410X26001957"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128387","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of high-risk human papillomavirus among women with different HPV-vaccination status in Sichuan, China","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128387","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"128387"}}